Advertisement
IDXX vs MLSS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDXX is a StrongBuy and MLSS is a StrongBuy.
IDXX in upward trend: 10-day moving average crossed above 50-day moving average on October 21, 2026
The 10-day moving average for IDXX crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 18 of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on IDXX as a result. In 56 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.
IDXX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +21.92% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDXX advanced for three days, in 177 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDXX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
IDXX broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 11 (best 1 - 100 worst), indicating outstanding price growth. IDXX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (32.832) is normal, around the industry mean (65.986). P/E Ratio (46.963) is within average values for comparable stocks, (3.066). Projected Growth (PEG Ratio) (2.894) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (9.042) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDXX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
MLSS's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for MLSS turned positive on October 29, 2026. Looking at past instances where MLSS's MACD turned positive, the stock continued to rise in 38 of 46 cases over the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MLSS's RSI Oscillator exited the oversold zone, 18 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 69 cases where MLSS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
Following a +3.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where MLSS advanced for three days, in 179 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
MLSS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MLSS as a result. In 97 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLSS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MLSS entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. MLSS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.934) is normal, around the industry mean (4.946). P/E Ratio (-6.078) is within average values for comparable stocks, (38.797). MLSS's Projected Growth (PEG Ratio) (37.320) is very high in comparison to the industry average of (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (3.601) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLSS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
IDXX | MLSS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 35 | 57 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 86 Overvalued | 98 Overvalued | |
PROFIT vs RISK RATING 1..100 | 88 | 100 | |
SMR RATING 1..100 | 16 | 99 | |
PRICE GROWTH RATING 1..100 | 11 | 76 | |
P/E GROWTH RATING 1..100 | 75 | 21 | |
SEASONALITY SCORE 1..100 | 85 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IDXX's Valuation (86) in the Medical Specialties industry is in the same range as MLSS (98). This means that IDXX’s stock grew similarly to MLSS’s over the last 12 months.
IDXX's Profit vs Risk Rating (88) in the Medical Specialties industry is in the same range as MLSS (100). This means that IDXX’s stock grew similarly to MLSS’s over the last 12 months.
IDXX's SMR Rating (16) in the Medical Specialties industry is significantly better than the same rating for MLSS (99). This means that IDXX’s stock grew significantly faster than MLSS’s over the last 12 months.
IDXX's Price Growth Rating (11) in the Medical Specialties industry is somewhat better than the same rating for MLSS (76). This means that IDXX’s stock grew somewhat faster than MLSS’s over the last 12 months.
MLSS's P/E Growth Rating (21) in the Medical Specialties industry is somewhat better than the same rating for IDXX (75). This means that MLSS’s stock grew somewhat faster than IDXX’s over the last 12 months.
| IDXX | MLSS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 59% | 1 day ago 72% |
| Stochastic ODDS (%) | 1 day ago 63% | 1 day ago 81% |
| Momentum ODDS (%) | 1 day ago 60% | 2 days ago 90% |
| MACD ODDS (%) | N/A | 1 day ago 83% |
| TrendWeek ODDS (%) | 1 day ago 61% | 1 day ago 80% |
| TrendMonth ODDS (%) | 1 day ago 53% | 1 day ago 90% |
| Advances ODDS (%) | 1 day ago 61% | 15 days ago 78% |
| Declines ODDS (%) | 28 days ago 69% | 5 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 74% | 1 day ago 82% |
| Aroon ODDS (%) | N/A | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IDXX’s FA Score shows that 2 FA rating(s) are green while MLSS’s FA Score has 1 green FA rating(s).
- IDXX’s FA Score: 2 green, 3 red.
- MLSS’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IDXX’s TA Score shows that 4 TA indicator(s) are bullish while MLSS’s TA Score has 5 bullish TA indicator(s).
- IDXX’s TA Score: 4 bullish, 4 bearish.
- MLSS’s TA Score: 5 bullish, 3 bearish.
Price Growth
IDXX (@Medical Specialties) experienced а +19.74% price change this week, while MLSS (@Pharmaceuticals: Other) price change was +1.30% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -2.30%. For the same industry, the average monthly price growth was -5.24%, and the average quarterly price growth was +42.12%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.70%. For the same industry, the average monthly price growth was -1.70%, and the average quarterly price growth was +10.08%.
Reported Earning Dates
IDXX is expected to report earnings on Feb 08, 2027.
MLSS is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Medical Specialties (-2.30% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (-0.70% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
IDXX and
Correlation & Price change
A.I.dvisor indicates that over the last year, IDXX has been loosely correlated with ALGN. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if IDXX jumps, then ALGN could also see price increases.
| Ticker / NAME | Correlation To IDXX | 1D Price Change % | ||
|---|---|---|---|---|
| IDXX | 100% | +0.06% | ||
| ALGN - IDXX | 50% Loosely correlated | -1.65% | ||
| SYK - IDXX | 48% Loosely correlated | +1.22% | ||
| BLCO - IDXX | 45% Loosely correlated | +0.10% | ||
| SNN - IDXX | 44% Loosely correlated | -0.23% | ||
| STE - IDXX | 40% Loosely correlated | -0.86% | ||
More | ||||